Synapse - Works

Results (4640)

Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET)

Meeting Abstract

Hobday, T.; Yin, J.; Pettinger, A.; Strosberg, J.; Reidy-Lagunes, D.; Chen, H.; Erlichman, C.
Pancreas (2016)

Design of a phase 2, prospective, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of lanreotide depot 120 mg in patients with well differentiated, advanced lung, or thymus neuroendocrine tumors (NETs)

Meeting Abstract

Reidy-Lagunes, D.; Wolin, E. M.; Pitman-Lowenthal, S.; Cox, D.; Kulke, M. H.
Pancreas (2016)

Fulltext@MSK | Save

Is next-generation sequencing (NGS) ready for routine clinical practice in advanced well differentiated pancreatic neuroendocrine tumors (WD panNETs): Results of a prospective study utilizing MSK-IMPACT (Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets)

Meeting Abstract

Raj, N.; Soumerai, T.; Valentino, E.; Reidy-Lagunes, D.
Pancreas (2016)

Fulltext@MSK | Save

Identification of SETD2 genetic alterations in patients with advanced well differentiated pancreatic neuroendocrine tumors (WD panNETs)

Meeting Abstract

Raj, N.; Soumerai, T.; Valentino, E.; Reidy-Lagunes, D.
Pancreas (2016)

Fulltext@MSK | Save

Treatment response and outcomes of metastatic grade 3 (G3) pancreatic neuroendocrine carcinomas (HGNEC) based on pathologic differentiation (well differentiated (WDNEC) versus poorly differentiated (PDNEC))